Breaking News, Collaborations & Alliances

AMRI Licenses Cancer Program

Chai to take over tubulin compound

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

AMRI has signed an exclusive license agreement with Chai Therapeutics for the development of ALB 109564(a), AMRI’s novel tubulin inhibitor compound. The compound is in late Phase I testing for the treatment of cancer. This pact follows the exercise of an option to license the intellectual property, which was granted in March 2012 by AMRI to Bessor Pharma. Chai Therapeutics is an affiliate of Bessor Pharma, LLC. AMRI received an undisclosed license fee and reimbursement for certain costs a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters